Thirty renal transplant recipients, after transplantation, were tested weekly with the following assays: cytomegalovirus (CMV) antigenemia (pp65 Ag), plasma qualitative Amplicor CMV (P-AMP), plasma and peripheral blood leukocyte quantitative Amplicor CMV monitor (P-and PBL-CMM), peripheral blood leukocyte (PBL) quantitative Quantiplex bDNA CMV, version 2.0 (bDNA), and whole-blood Nuclisens pp67 CMV (pp67). Eleven patients developed symptomatic CMV disease, and 7 developed asymptomatic CMV infection. For prediction of CMV disease, the sensitivity, specificity, and positive and negative predictive values, respectively, were as follows: 100%, 63%, 61%, and 100% for pp65 Ag; 100%, 42%, 50%, and 100% for bDNA; 91%, 47%, 50%, and 90% for PBL-CMM; 55%, 74%, 55%, and 74% for P-AMP; 55%, 74%, 55%, and 74% for P-CMM; and 64%, 79%, 64%, and 79% for pp67. First positive results in PBL were obtained 9-10 days before symptoms of CMV disease, compared with 5-6 days in plasma and 0 days in whole blood. PBL assays appear to be more appropriate than plasma assays when pre-emptive therapy is required to prevent the rapid progression from the first detection of the virus to CMV disease.
New Molecular Assays to Predict Occurrence of Cytomegalovirus Disease in Renal Transplant Recipients
Human cytomegalovirus (HCMV) disease in renal transplant recipients has a major impact on morbidity and mortality [1] . Although 20%-60% of renal transplant recipients develop symptomatic CMV disease (S-CMV), usually within the first 3 months after transplantation, 60%-90% of all renal transplant candidates have latent CMV infections [2] [3] [4] . It has been suggested that HCMV plays a role in graft rejection by inducing the expression of class I and class II histocompatibility antigens on infected cells and increasing T-lymphocyte cytotoxic response [5] [6] [7] . Sensitive and specific assays for the early detection of HCMV infection are required in monitoring transplant patients. This precocity is essential for timely application of antiviral therapy. Nevertheless, detection of CMV in samples may represent asymptomatic viral shedding and does not necessarily indicate the presence of current or impending symptomatic disease.
Qualitative and quantitative techniques, including assays for pp65 antigenemia (pp65 Ag), CMV DNA amplification in pe-ripheral blood leukocytes (PBL) and plasma, and CMV late mRNA amplification have been considered sensitive and accurate means for determining CMV loads in different blood compartments [8] [9] [10] [11] [12] [13] and have been used to correlate viremia levels with occurrence and severity of disease [14, 15] . The aim of this study was to compare 6 CMV assays, including testing for levels of CMV pp65 antigenemia (pp65 Ag; the present gold standard) for their usefulness in deciding whether to use preemptive therapy in renal transplant recipients and in monitoring patient response to treatment in the first 12 weeks after renal transplantation.
Materials and Methods
Patients and specimen collection. Whole blood (WB), PBL, and plasma were collected prospectively at least weekly from 30 consecutive renal transplant recipients at the Bordeaux University Hospital, France. After renal transplantation, 2 distinct immunosuppressive regimens were used. The first was a 3-drug treatment combining cyclosporin A or tacrolimus, azathioprine or mycophenolate mofetil, and corticosteroids. Treatment was started on the day of transplantation, and the initially high doses of corticosteroids were gradually decreased until 3 months after transplantation. The second regimen combined sequential use of 4 drugs, beginning with a 10-day induction with anti-thymocyte globulins (Fresenius, Bad Homburg, Germany), followed by the same 3-drug combination used in the first regimen.
Clinical records were retrospectively reviewed for case definition, by a physician who was not aware of the laboratory results. S-CMV was defined as positive pp65 Ag results plus unexplained fever or leukopenia (!3 ϫ 10 9 /L on 2 consecutive occasions) or both, thrombocytopenia (!5 ϫ 10 9 /L on 2 consecutive occasions), unexplained elevated aminotransferase levels (150% above normal), or tissue-invasive CMV infection. Asymptomatic CMV infection (AS-CMV) was defined as positive pp65 Ag results at least once, without specific clinical symptoms. Subjects defined as healthy never displayed any CMV disease symptom and never had positive pp65 Ag results throughout the follow-up period.
The decision to treat with intravenous ganciclovir (IV-GCV) was made on the basis of clinical symptoms or positive pp65 Ag results. The treatment protocol consisted of 3 weeks of full-dose IV-GCV (10 mg/kg per day, 5 days per week), followed by 2 months of halfdose IV-GCV (5 mg/kg per day 5 days per week).
Patients were followed weekly for у12 weeks, and they were seen twice a week when they developed AS-CMV or S-CMV infection. Blood samples were serially collected into heparin for pp65 Ag assays and into EDTA for the plasma qualitative Amplicor CMV (P-AMP), plasma quantitative Amplicor CMV monitor (P-CMM), peripheral blood leukocyte (PBL) quantitative Amplicor CMV monitor (PBL-CMM), PBL quantitative Quantiplex bDNA CMV, version 2 (bDNA), and whole-blood Nuclisens pp67 CMV (pp67) assays.
CMV assays. pp65 Ag (HCMV antigenemia immunofluorescent kit; Argene Biosoft, Varilhes, France) was measured after immunofluorescent staining of PBL cytospin preparations, according to the manufacturer's recommendations. Results are expressed as the number of CMV antigen-positive cells per 200,000 PBL, and the test was considered to be positive when у1 fluorescent cell(s) was observed.
The P-AMP test (Amplicor CMV assay; Roche Diagnostics, Basel, Switzerland), a polymerase chain reaction (PCR) qualitative test for the detection of CMV DNA in plasma, was performed according to the manufacturer's instructions and as described elsewhere [16] . The limit of detection of this qualitative assay is 1000 copies of CMV DNA per milliliter of serum.
CMM (Amplicor CMV monitor assay, Roche Diagnostics) is a new quantitative PCR test for CMV DNA in plasma and PBL. In brief, CMV DNA was extracted from 200 mL of plasma or from 10 6 PBL with 600 mL of CMV monitor lysis reagent containing a known number of quantitation-standard DNA molecules. The DNA was precipitated with isopropanol, recovered by microcentrifugation at maximum speed (у12,500 g) for 15 min at room temperature, washed with 1 mL of 70% ethanol, and resuspended in 400 mL of CMV monitor specimen diluent. Fifty microliters of the processed specimen was added to 50 mL of CMV monitor master mix for PCR amplifications. Amplification and detection were automatically performed by the Cobas Amplicor System. Results were expressed as an optical density of 660 nm and as copies per milliliter of serum or per 10 6 PBL. One CMV monitor lowpositive control, 1 CMV monitor high-positive control, and 1 CMM-negative control were processed with each batch of specimens. Assays were considered valid when an individual specimen had optical density values for CMV and quantitation standard of 0.2-2.0. Any specimen with a quantitation standard optical density that did not meet these criteria was considered invalid. The limit of detection of this quantitative assay is 400 copies of CMV DNA per milliliter or per 10 6 PBL. Cellular loads of CMV were quantitated with bDNA (Chiron, Emeryville, CA). This new technology is based on the hybridization of 43 distinct oligonucleotide probes complementary to the gB gene (major envelope glycoprotein) of the CMV genome. All specimens were tested in duplicate, and CMV DNA was compared with a standard curve of CMV DNA performed in parallel for each assay. Samples were assayed in the semiautomatic 340 bDNA analyzer. The limit of detection of this quantitative assay is 900 copies of CMV DNA per 10 6 PBL. pp67 (Nuclisens pp67, Organon Teknika Diagnostics, Boxtel, The Netherlands) is an isothermal nucleic acid amplification reaction that enables detection of the presence of CMV pp67 mRNA in human anticoagulated WB. For analysis, 1 mL of lysed WB suspension, which equals 100 mL of WB input sample, was used. Twenty microliters of CMV control RNA containing 3000 copies of pp67 system control RNA was added. Nucleic acids were isolated essentially as described by Boom et al. [17] . The primers, CMV pp67-1.2 and CMV pp67-2.4, were designed to amplify the part of the mRNA encoding pp67 [18] . Nucleic acid sequencebased amplification reactions were carried out as described by Kievits et al. [19] . The analytical sensitivity threshold of this assay was 160-280 molecules of RNA [20] .
Statistical analysis. Percentages were compared among groups by Fisher's exact test. Means were compared among groups by Student's t test or the Wilcoxon test. Concordance among the pp65 Ag, PBL-CMM, bDNA, P-AMP, P-CMM, and pp67 assays was assessed with the k coefficient of concordance.
Positive and negative predictive values of CMV assays to detect AS-CMV and S-CMV infection were estimated by the prevalences of CMV infection and disease in the study population. The sensitivity and specificity of each assay to detect or predict AS-CMV or S-CMV, were estimated after defining positivity as у1 positive pp65 Ag test, either before the diagnosis of AS-or S-CMV or, for patients without AS-CMV or S-CMV, by the time of the last followup visit. A patient was considered healthy when all assays remained negative throughout the entire follow-up period.
Results
Patients. Thirty kidney-allograft recipients (16 men and 14 women; mean age ‫ע‬ SD, 40.1 ‫ע‬ 13.3 years), among whom 27 patients had received their first renal transplant, were consecutively enrolled between February 1998 and August 1998. Among them, 16 benefited from sequential immunosuppressive quadruple therapy with anti-thymocyte globulin induction. There was no significant difference between S-CMV or AS-CMV transplant recipients in terms of age, sex ratio, induction treatment with anti-thymocyte globulin, duration of cold ischemia, appearance of early acute tubular necrosis, or onset of acute rejection. None of the patients received prophylaxis against CMV. The median (25th, 75th percentiles) time between renal transplantation and inclusion was 6 days (3, 8 days) and median (25th, 75th percentiles) follow-up was 106 days (86, 125 days).
During the first 3 months after transplantation, S-CMV occurred in 11 patients (36.7%), with у2 diagnostic criteria for CMV disease present in 4 of them. AS-CMV occurred in 7 NOTE. pp65 Ag, CMV antigenemia assay; bDNA, branched DNA CMV assay; PBL-CMM, peripheral blood leukocyte quantitative Amplicor CMV monitor assay; P-AMP, plasma qualitative Amplicor CMV assay; P-CMM, plasma quantitative Amplicor CMV monitor assay; pp67, whole-blood Nuclisens pp67 CMV assay. patients (23.3%), and 12 subjects (40%) remained uninfected by CMV.
Median (25th, 75th percentiles) times to the first positive pp65 Ag test and the first symptoms of CMV disease were 30.5 days (27, 42 days) and 37 days (27, 78 days) after transplantation, respectively.
Among the 7 patients with AS-CMV infection, 3 belonged to the donor-positive (D ϩ )/recipient-negative (R Ϫ ) serogroup, 3 to the donor-negative (D Ϫ )/recipient-positive (R ϩ ) serogroup, and 1 to the D ϩ /R ϩ serogroup. Among the 11 patients with S-CMV infection, 2 belonged to the D ϩ /R Ϫ serogroup, 3 to the D Ϫ /R ϩ serogroup, and 6 to the D ϩ /R ϩ serogroup. Thus, seropositive patients who had received a kidney from a seropositive donor showed the highest incidence of S-CMV (50%; 6 of 12). One-third of the D ϩ /R Ϫ (2 of 6) and the D Ϫ /R ϩ (3 of 9) serogroups developed S-CMV. All 3 patients from the D Ϫ /R Ϫ serogroup remained healthy. No significant relationship was found between the D/R serostatus and the clinical or biological pattern of CMV evolution (P = .21). All 11 S-CMV patients and 4 of the patients with AS-CMV received IV-GCV antiviral therapy.
Laboratory assays. A total of 283 sets of samples collected from the 30 renal transplant recipients was tested with the 6 CMV assays. Among subjects who developed S-CMV, a median of 15 samples was analyzed, and a median of 13 samples was analyzed for subjects who had AS-CMV or were healthy.
Agreement of qualitative results among CMV assays. The concordance among the 6 assays used to test the 283 samples is reported in table 1. Good agreement was found among the 6 assays (range, 75.6%-93.3%), as well as among assays assessing CMV loads in PBL compartment (range, 79.5%-83% with pp65 Ag, bDNA, and PBL-CMM) and among those assessing CMV loads in PBL versus plasma or WB (range, 75.6%-86.9%). Most cases of discordance between CMV assays were observed at the beginning, when active CMV replication could be measured, or during CMV clearance in response to antiviral therapy. Some discordant results were obtained for patients who previously or subsequently presented a concordant result during the course of CMV infection; for these samples, the discordance may be attributable to disease kinetics rather than to the performances of the tests. Moreover, in most cases of discordant results, the positive quantitative assays showed low CMV loads: medians were 5 positive cells with pp65 Ag, 1800 copies/mL with P-CMM, 1100 copies/10 6 PBL with PBL-CMM, and 1800 copies/10 6 PBL with bDNA.
Abilities of the 5 CMV assays to detect CMV infection.
The abilities of the assays to detect CMV infection were assessed by considering all the measurements made throughout the entire follow-up period for the 30 renal transplant recipients. For this purpose, patients were divided into 2 groups: the first comprised patients who had positive results with the pp65 Ag assay and who had у1 positive test result with any of the other 5 assays (before the first pp65 Ag-positive result for infected patients or until the last follow-up visit for pp65 Ag-negative patients), and the second comprised those who had no positive results during the entire study period. To detect CMV infection, the highest estimations of sensitivity and negative predictive values (190%) were obtained with PBL assays; the highest estimations of specificity and positive predictive values (191%) were obtained with P-AMP, P-CMM, and WB pp67 assays (table 2) . Despite positive pp65 Ag and bDNA results for the 18 patients with CMV infection, the assays of either plasma or WB or both remained negative for 8 patients assessed with P-AMP, for 7 assessed with P-CMM, and for 7 assessed with pp67.
Abilities of the 6 CMV assays to predict S-CMV. To predict S-CMV, the highest estimations of sensitivity and negative predictive values (190%) were again obtained with PBL assays, and the highest estimations of specificity (174%) and positive predictive values (55%-64%) were obtained with plasma and WB assays (table 2) . Qualitative and quantitative plasma PCR assays had equivalent abilities to predict the occurrence of CMV disease. Despite positive pp65 Ag and bDNA results for the 11 S-CMV patients, the other assays remained negative for 5 patients assessed with P-AMP, for 5 assessed with P-CMM, and for 4 assessed with pp67.
Kinetics of CMV markers before detection of CMV infection and diagnosis of S-CMV.
After the first positive pp65 Ag result, the median numbers of days (25th, 75th percentiles) to positivity with the 5 other assays were as follows: 0 days (0, 6 days) with bDNA, 3 days (0, 16 days) with PBL-CMM, 6 days (0, 10 days) with P-CMM or pp67, and 7 days (0, 10 days) with P-AMP assays. The first positive samples before S-CMV are presented in table 2.
At the time of S-CMV diagnosis, the median (25th, 75th percentiles) CMV loads were as follows: 6 positive cells (3, 48 positive cells) per 2 ϫ 10 5 PBL with pp65 Ag; 17,930 copies NOTE. PBL, peripheral blood leukocyte; WB, whole blood; pp67, WB Nuclisens pp67 CMV assay; pp65 Ag, CMV antigenemia assay; bDNA, branched DNA CMV assay; PBL-CMM, quantitative Amplicor CMV monitor assay; P-AMP, plasma qualitative Amplicor CMV assay; P-CMM, plasma quantitative Amplicor CMV monitor assay; S-CMV, symptomatic CMV disease.
a Defined by 1 positive pp65 Ag result. b Nos. of patients among the 18 positive pp65 whose CMV assays remained negative. c Nos. of patients among the 11 with S-CMV and positive pp65 Ag and bDNA results whose other CMV assays remained negative.
(900, 83,950 copies)/10 6 PBL with bDNA; 7330 copies (400, 19,300 copies)/10 6 PBL with PBL-CMM; and 2370 copies (400, 14,700 copies)/mL with P-CMM.
During the period of analysis, comparison of the maximum HCMV loads detected did not demonstrate any significant differences between AS-CMV and S-CMV (data not shown). This similarity may be explained by the very wide interpatient variability and the relatively small number of patients.
Kinetics of CMV markers during and after antiviral therapy. The IV-GCV treatment was initiated at a median (25th, 75th percentiles) of 6 days (0, 13 days) after the first positive pp65 Ag result and was maintained for 45 days (22, 67 days ). The full dose was given for 26 days (22, 34 days), and the half dose was given for 37 days (28, 44 days). During treatment, the results of all 6 assays became negative in 7 patients, 2 of whom (patients 3 and 13) relapsed 2 and 4 weeks, respectively, after stopping IV-GCV treatment (table 3) . At the end of GCV treatment, the results of у1 PBL assay remained positive in the other 8 patients, 4 of whom also had positive plasma assay results (patients 5, 8, 9, and 10). Four of 8 subjects showed biological signs of relapse, with active replication detected in plasma (patients 5, 9, 11, and 14) 1-6 weeks after the end of treatment. Again, in most cases, the biological relapse was detected first with PBL assays. Results of PBL assays were positive only in patients 8 and 15 (у2 positive test results each), and no clinical symptoms were present. The positive results of the PBL and plasma assays of patient 10 at the end of treatment became negative and remained so at the end of the follow-up (45 days after the end of treatment), without further therapeutic intervention. Moreover, virus was cleared from the blood of 1 renal transplant recipient who had moderate viremia but received no antiviral therapy. This observation suggests that, among transplant recipients, recovery of the immune system may be sufficient to resolve HCMV infection in blood.
Discussion
The incidence of CMV disease did not differ significantly between seropositive patients receiving grafts from seropositive donors and those receiving grafts from seronegative donors. This finding is in contrast with a previous study in which CMV disease was found to occur significantly more often in CMVpositive patients receiving CMV positive organs [21] but is in agreement with the study by Eriksson et al. [22] .
To identify new CMV assays with the best abilities to predict CMV disease occurrence, we compared the abilities of 6 quantitative or qualitative assays to measure CMV loads in plasma, PBL, and WB from serial samples drawn from 30 patients during the first 12 weeks after renal transplantation.
The appearance of pp65 Ag (an early structural virus protein) in PBL has proven to be a sensitive and, in CMV disease, a well-correlated marker in organ-transplant recipients [23] [24] [25] . However, its use for routine detection is hampered, because pp65 Ag seems to be rapidly degraded in antigen-bearing cells [26] [27] [28] . In accordance with Meyer-Kö nig et al. [24] , we found that the pp65 Ag test was superior to the PBL CMV DNA assay in regard to specificity and positive predictive values. However, considering the much higher stability of CMV DNA, compared with pp65 antigens in blood samples processed after a delay, CMV DNA detection or quantitation in PBL by molecular methods should be regarded as a promising alternative to the pp65 Ag assay. Whether PBL, plasma, or WB is the best specimen for detection of CMV DNA in blood still needs to be determined and probably depends on what sort of patient population is being considered. Plasma offers the advantage of easier specimen processing and handling; moreover, it is possible to detect HCMV in neutropenic patients [29] . Although less sensitive than PBL PCR measures for identifying active infection, CMV PCR in plasma showed higher specificity of positive results with respect to active CMV infection. The association of S-CMV with plasma DNA in a single sample has been reported by some investigators [30] [31] [32] , but others have not found this relationship [33] . In the present study, even though specificities of plasma assays were the highest, we found high copy numbers in plasma from some patients with AS-CMV (patients 6, 10, and 13) and low copy numbers in some patients with S-CMV (patients 1, 3, and 4).
During antiviral treatment, plasma DNA levels are often low and disappear early, whereas PBL DNA levels may be much higher and persist much longer [34] . In our previous study of AIDS patients [16] , we demonstrated that CMV quantitation in plasma provided information early enough to allow effective preemptive therapy for individuals infected with the human immunodeficiency virus, in whom the progression from first detection of CMV DNA to disease can last several weeks or months. In contrast, in the present study of renal transplant recipients, we showed that the use of PBL may be more appropriate, because preemptive therapy is often prescribed in a setting in which there is rapid progression from first detection of CMV DNA to S-CMV. Moreover, CMV DNA levels in PBL should be particularly helpful in monitoring the response to treatment and in individualizing the length of therapy. Finally, it may serve as an indicator of drug resistance. Plasma DNA levels do not seem to be sufficiently sensitive for such purposes.
In the present study, the best sensitivity and negative predictive values (190%) and the earliest positive results before CMV disease, other than those provided by the pp65 Ag assay (the current gold standard), were obtained with PBL assays. The kinetics of PBL DNA appeared to grossly parallel those of pp65 Ag. After antiviral therapy, detection of HCMV DNA in PBL indicates a continued risk of resumption of viral replication, which can result in the reappearance of viremia and overt disease. However, among the successfully treated patients (patients with all assays negative at the end of treatment), 2 patients (patients 3 and 13) showed a recurrence within the first month after the end of antiviral therapy, suggesting that treatment is responsible for suppression of viral replication rather than eradication of virus.
The analysis of late viral transcripts by use of the pp67 assay should be more relevant for detection of active CMV replication, because transcription of the viral genome is repressed during latency. In this study, the pp67 mRNA amplification was highly specific for active CMV infection and CMV disease, but in 7 of 18 AS-CMV patients and in 4 of 11 S-CMV patients, the mRNA transcripts were not detected. Our results are not in agreement with those of Meyer et al. [35] , who found that CMV transcripts allowed differentiation of active and non-active infection, or with those of Gaeta et al. [36] , who found late transcript detection to be more informative concerning viral replication status during follow-up of S-CMV patients who were receiving antiviral therapy. Indeed, in our study, no patient who had a biological relapse had a positive mRNA PCR at the end of the treatment. Thus, PCR-based RNA detection does not seem to be the optimal assay for the diagnosis of disease or the determination of the end of viral replication during antiviral therapy.
CMV loads were similar in AS-CMV and S-CMV subjects when we used bDNA or PBL-CMM, whereas a trend toward higher CMV loads was found with P-CMM and pp65 Ag among S-CMV subjects. Our results are not in concordance with those of Roberts et al. [37] and Kü hn et al. [38] , who observed higher CMV DNA levels in subjects with S-CMV. This discrepancy may be explained by the variations between studies regarding CMV disease definitions, by the variations in population sizes, or by the fact that several subjects in this study received IV-GCV as soon as pp65 Ag was detected. Moreover, the assignment of patients to S-CMV or AS-CMV categories may be subject to error, because clinical manifestations of CMV disease are often nonspecific.
Our results shed doubt on the clinical significance and usefulness of determining plasma DNA levels alone in immunocompromised renal transplant recipients. On the basis of this study, when results of the PBL CMV PCR assay are negative, we can conclude with confidence that the patient is unlikely to have active CMV disease. When results of this assay are positive, a plasma CMV PCR analysis must be performed to characterize the CMV replicative activity. Although the number of patients in this study is limited, information gathered during follow-up suggests that once antiviral induction treatment is initiated it should be continued until not only plasma DNA but also pp65 Ag and/or PBL DNA become negative. Whether treatment should be stopped may be decided more safely on the basis of a progressive decrease in PBL DNA levels until they disappear. Therefore, the disappearance of PBL DNA or pp65 Ag or both may represent a primary end point that must be met during antiviral therapy to delay or prevent the relapse of HCMV infection or disease [39] . A positive PCR assay after IV-GCV therapy may be an indication that this drug should be continued or, perhaps, that another drug should be initiated along with the search for ganciclovir resistance.
